Cargando…
Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials
Artemisinin and its derivatives have shown broad-spectrum antitumor activities in vitro and in vivo. Furthermore, outcomes from a limited number of clinical trials provide encouraging evidence for their excellent antitumor activities. However, some problems such as poor solubility, toxicity and cont...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573816/ https://www.ncbi.nlm.nih.gov/pubmed/33117153 http://dx.doi.org/10.3389/fphar.2020.529881 |
_version_ | 1783597516896337920 |
---|---|
author | Xu, Cangcang Zhang, Huihui Mu, Lingli Yang, Xiaoping |
author_facet | Xu, Cangcang Zhang, Huihui Mu, Lingli Yang, Xiaoping |
author_sort | Xu, Cangcang |
collection | PubMed |
description | Artemisinin and its derivatives have shown broad-spectrum antitumor activities in vitro and in vivo. Furthermore, outcomes from a limited number of clinical trials provide encouraging evidence for their excellent antitumor activities. However, some problems such as poor solubility, toxicity and controversial mechanisms of action hamper their use as effective antitumor agents in the clinic. In order to accelerate the use of ARTs in the clinic, researchers have recently developed novel therapeutic approaches including developing novel derivatives, manufacturing novel nano-formulations, and combining ARTs with other drugs for cancer therapy. The related mechanisms of action were explored. This review describes ARTs used to induce non-apoptotic cell death containing oncosis, autophagy, and ferroptosis. Moreover, it highlights the ARTs-caused effects on cancer metabolism, immunosuppression and cancer stem cells and discusses clinical trials of ARTs used to treat cancer. The review provides additional insight into the molecular mechanism of action of ARTs and their considerable clinical potential. |
format | Online Article Text |
id | pubmed-7573816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75738162020-10-27 Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials Xu, Cangcang Zhang, Huihui Mu, Lingli Yang, Xiaoping Front Pharmacol Pharmacology Artemisinin and its derivatives have shown broad-spectrum antitumor activities in vitro and in vivo. Furthermore, outcomes from a limited number of clinical trials provide encouraging evidence for their excellent antitumor activities. However, some problems such as poor solubility, toxicity and controversial mechanisms of action hamper their use as effective antitumor agents in the clinic. In order to accelerate the use of ARTs in the clinic, researchers have recently developed novel therapeutic approaches including developing novel derivatives, manufacturing novel nano-formulations, and combining ARTs with other drugs for cancer therapy. The related mechanisms of action were explored. This review describes ARTs used to induce non-apoptotic cell death containing oncosis, autophagy, and ferroptosis. Moreover, it highlights the ARTs-caused effects on cancer metabolism, immunosuppression and cancer stem cells and discusses clinical trials of ARTs used to treat cancer. The review provides additional insight into the molecular mechanism of action of ARTs and their considerable clinical potential. Frontiers Media S.A. 2020-10-06 /pmc/articles/PMC7573816/ /pubmed/33117153 http://dx.doi.org/10.3389/fphar.2020.529881 Text en Copyright © 2020 Xu, Zhang, Mu and Yang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Xu, Cangcang Zhang, Huihui Mu, Lingli Yang, Xiaoping Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials |
title | Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials |
title_full | Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials |
title_fullStr | Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials |
title_full_unstemmed | Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials |
title_short | Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials |
title_sort | artemisinins as anticancer drugs: novel therapeutic approaches, molecular mechanisms, and clinical trials |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573816/ https://www.ncbi.nlm.nih.gov/pubmed/33117153 http://dx.doi.org/10.3389/fphar.2020.529881 |
work_keys_str_mv | AT xucangcang artemisininsasanticancerdrugsnoveltherapeuticapproachesmolecularmechanismsandclinicaltrials AT zhanghuihui artemisininsasanticancerdrugsnoveltherapeuticapproachesmolecularmechanismsandclinicaltrials AT mulingli artemisininsasanticancerdrugsnoveltherapeuticapproachesmolecularmechanismsandclinicaltrials AT yangxiaoping artemisininsasanticancerdrugsnoveltherapeuticapproachesmolecularmechanismsandclinicaltrials |